Patients with psoriasis using an IL-17A inhibitor had an increased risk of oral candidiasis and outpatient infections but no increase for MACE, anaphylaxis, or malignancy compared to other biologics.
FBI Reform - fbireform.comFBI Reform - fbireform.com - The News And Times